Floatz logo

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)

Metastatic Malignant Neoplasm

Washington University School of Medicineprotein_peptidePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

275 Active assets in the Metastatic Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
51 / 100
View asset →
invasive ductal breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →